64,85 €
2,40 %vorgestern
L&S, 23. Februar, 22:53 Uhr
ISIN
US46116X1019
Symbol
ITCI
Berichte
Sektor
Industrie

Intra-Cellular Therapies, Inc. Aktie News

Neutral
Seeking Alpha
3 Tage alt
Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
3 Tage alt
Full year 2023 total revenues of $464.4 million , compared to $250.3 million in 2022
Positiv
InvestorPlace
4 Tage alt
Now that the FED is looking to lower interest rates this year, cheaper money and more accessible financing will let investors venture into riskier places in the economy and the stock market. While not that risky of an industry, the biotech space can often be speculative.
Positiv
Investors Business Daily
12 Tage alt
Among the best stocks to buy and watch, Intra-Cellular Therapies is approaching a new buy point ahead of its earnings results.
Positiv
Seeking Alpha
15 Tage alt
Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significant revenue growth. Intra-Cellular is running Phase 3 studies to expand Caplyta's label into major depressive disorder, presenting a potential future growth opportunity.
Neutral
GlobeNewsWire
17 Tage alt
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 22, 2024, to provide a corporate update and di...
Neutral
GlobeNewsWire
etwa 2 Monate alt
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, ...
Positiv
Seeking Alpha
etwa 2 Monate alt
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen